Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name AK001796
   Synonyms MIR4435-2HG, AGD2, AK001796, LINC00978, MIR4435-1HG, MIR4435-2HG
   Region GRCh38_2:111036776-111523376    Sequence
   Ensembl ENSG00000172965
   RefSeq NR_015395
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name lung cancer
   ICD-0-3 C34  
   Methods microarray, qPCR, RNAi, Cell proliferation assay etc.
   Sample lung cancer tissues, cell lines (BEAS-2B, A549 and H446)
   Expression Pattern up-regulated
   Function Description

AK001796, the lncRNA with the most clearly altered expression, was overexpressed in lung cancer tissues and cell lines, but its expression was downregulated in resveratrol-treated lung cancer cells. By monitoring cell proliferation and growth in vitro and tumor growth in vivo, we observed a significant reduction in cell viability in lung cancer cells and a slow growth in the tumorigenesis following AK001796 knockdown. We also found that AK001796 knockdown caused a cell-cycle arrest, with significant increases in the percentage of cells in G0/G1 in lung cancer cells. By using cell cycle pathway-specific PCR arrays, we detected changes in a number of cell cycle-related genes related to lncRNA AK001796 knockdown.

   Pubmed ID 25888808
   Year 2015
   Title A novel long noncoding RNA AK001796 acts as an oncogene and is involved in cell growth inhibition by resveratrol in lung cancer.
   External Links
   Links for  AK001796 GenBank       HGNC       lncrnadb       Noncode
   Links for  lung cancer Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.